# Microplastics in Blood, Placenta, Plaque, and Brain: What Studies Show

> Detection is no longer speculative—Leslie blood, Ragusa placenta, Marfella plaque, and Nihart brain findings—with hard limits on causation.

*Published 2026-07-10 · Updated 2026-07-10 · By Elena Voss*

In short

Multiple groups have detected micro- and nanoplastics in **human blood, placenta, carotid plaque, and brain**. That establishes bioavailability—not disease causation by itself. Landmark anchors: Leslie 2022 blood (~77% positive), Ragusa 2021 placenta, Marfella 2024 NEJM plaque-outcome association, Nihart 2025 brain enrichment.

Five years ago, “plastics in organs” was mostly environmental metaphor. It is now a set of peer-reviewed human tissue findings. Keep two questions separate: *Is it there?* and *Does dose cause harm?*

*This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.*

## Which human studies first put plastics inside the body?

**Blood — Leslie et al., 2022.** Using pyrolysis-GC/MS, researchers reported plastic polymers in whole blood from **17 of 22 donors (~77%)**, including PET, polyethylene, styrene polymers, PMMA, and polypropylene ([PubMed](https://pubmed.ncbi.nlm.nih.gov/35367073/)). Small n, careful contamination controls required, but the study shifted the burden of proof toward internal exposure being common in sampled adults.

**Placenta — Ragusa et al., 2021 (“Plasticenta”).** Raman microspectroscopy identified **12 microplastic fragments (5–10 µm)** across **4 of 6** placentas, on maternal and fetal sides and membranes. Barrier crossing elevates developmental research priority even when clinical outcome data remain limited.

  Landmark human microplastic deposition studies
  SiteStudyKey quantitative noteWhat it does not prove

    BloodLeslie 2022~77% donors polymer-positiveClinical disease threshold
    PlacentaRagusa 20214/6 placentas; 5–10 µm fragmentsBirth-outcome causation
    Carotid plaqueMarfella 2024 NEJM58.4% plaques MNP-positive; higher MI/stroke/death compositeSettled causal mechanism
    BrainNihart 2025 Nat Med~7–30× polymer mass vs liver/kidneyIndividual dementia diagnosis

## What did Marfella 2024 add beyond “plastics are present”?

In patients undergoing carotid endarterectomy, Marfella et al. found micro- and nanoplastics in plaque of **150/257 (58.4%)** participants. Those with detected plastics had higher subsequent risk of the composite of myocardial infarction, stroke, or death versus plastic-negative plaque patients. Always cite the [NEJM primary report](https://www.nejm.org/doi/full/10.1056/NEJMoa2309822) for exact hazard ratios and confidence intervals. Critical framing: observational association in diseased arteries of a surgical population—not settled mechanism language that “microplastics cause heart attacks.”

## What does brain deposition evidence say—and how careful should we be?

Nihart et al. (Nature Medicine, 2025) reported micro- and nanoplastic polymer concentrations in decedent brains roughly **7–30 times** those in liver or kidney, with polyethylene prominent and higher concentrations in more recent archival samples. Dementia subgroup findings were reported with caution. Post-mortem work plus polymer analytics invite contamination and method debates; expert commentary urged against simplistic “plastic spoon” dose metaphors.

Method caveats apply to every organ paper: mass spectrometry polymer mass is not the same as counted particles under microscopy; blank controls, laboratory air, and reagents can confound; nanoplastics are harder than microplastics. Cross-study numerical comparisons without method alignment mislead.

## How should readers hold presence, association, and action?

**Presence** is multi-organ and multi-group. **Association** with hard outcomes is strongest so far in the plaque-cardiovascular composite setting, still observational. **Causation and safe thresholds** are not established for routine clinical counseling the way lead MCLs are. Low-regret exposure reduction—less heated plastic food contact, dust control, thoughtful packaging—can proceed without a validated “detox.” Population materials policy will matter more than any single consumer ritual.

## What should careful readers do with this evidence?

Use primary sources linked in this article before changing household systems, training plans, or clinical conversations. Prefer measurements—lab panels, water tests, training logs, or certified product listings—over marketing claims. When evidence is observational, say so out loud: associations can guide research priorities and low-regret habits without becoming promises of disease prevention. When guidance bodies publish cutoffs or MCLs, treat them as the public reference layer and verify whether your situation is inside that legal or clinical scope. Re-check living agency pages because regulations and practice guidelines update. If two reputable sources disagree, dual-source the claim and prefer the document that states methods, units, and populations clearly. Finally, keep sex, age, pregnancy, and comorbidity modifiers in view whenever the underlying literature is limited to one demographic group.

Health Canon’s editorial standard ranks large controlled trials and codified regulations above single cohorts; cohorts above mechanism speculation; marketing last. The goal of densifying this topic cluster is enough depth that a reader can act without outsourcing judgment to a headline. If you only remember one habit from this page, make it the habit of asking for units, sample, and maintenance or adherence conditions before trusting a number.

## What should careful readers do with this evidence?

Use primary sources linked in this article before changing household systems, training plans, or clinical conversations. Prefer measurements—lab panels, water tests, training logs, or certified product listings—over marketing claims. When evidence is observational, say so out loud: associations can guide research priorities and low-regret habits without becoming promises of disease prevention. When guidance bodies publish cutoffs or MCLs, treat them as the public reference layer and verify whether your situation is inside that legal or clinical scope. Re-check living agency pages because regulations and practice guidelines update. If two reputable sources disagree, dual-source the claim and prefer the document that states methods, units, and populations clearly. Finally, keep sex, age, pregnancy, and comorbidity modifiers in view whenever the underlying literature is limited to one demographic group.

Health Canon’s editorial standard ranks large controlled trials and codified regulations above single cohorts; cohorts above mechanism speculation; marketing last. The goal of densifying this topic cluster is enough depth that a reader can act without outsourcing judgment to a headline. If you only remember one habit from this page, make it the habit of asking for units, sample, and maintenance or adherence conditions before trusting a number.

## Sources

1. [Discovery and quantification of plastic particles in human blood](https://pubmed.ncbi.nlm.nih.gov/35367073/)
2. [Plasticenta: first evidence of microplastics in human placenta](https://pubmed.ncbi.nlm.nih.gov/33395930/)
3. [Microplastics and nanoplastics in atheromas and cardiovascular events](https://www.nejm.org/doi/full/10.1056/NEJMoa2309822)
4. [Bioaccumulation of microplastics in decedent human brains](https://www.nature.com/articles/s41591-024-03453-1)

---
Source: https://healthcanon.com/environmental-health/microplastics-in-blood-and-organs
Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt